Objectives: To investigate patterns of early repeat prescriptions and treatment switching over an 11-year period to estimate differences in the cost of medication wastage, dispensing fees and prescriber time for short (<60 days) and long (≥60 days) prescription lengths from the perspective of the National Health Service in the United Kingdom. Setting: Retrospective, multiple cohort study of primary care prescriptions from the Clinical Practice Research Datalink. Participants: Five random samples of 50,000 patients each prescribed oral drugs for (1) glucose control in type 2 diabetes mellitus (T2DM), (2) hypertension in T2DM, (3) statins (lipid management) in T2DM, (4) secondary prevention of myocardial infarction and (5) depression. Pri...
Aims UK guidelines for type II diabetes leave the choice of glucose lowering therapies after metform...
This is the author accepted manuscript. The final version is available from the publisher via the DO...
Background: Two alternative basal analogue insulin treatments are available: insulin glargine (glarg...
OBJECTIVES: To investigate patterns of early repeat prescriptions and treatment switching over an 11...
Objectives: To investigate patterns of early repeat prescriptions and treatment switching over an 11...
Background: The National Health Service (NHS) in England spends over £9 billion on prescription medi...
BACKGROUND: To reduce expenditure on, and wastage of, drugs, some commissioners have encouraged gene...
Background: To reduce expenditure on, and wastage of, drugs, some commissioners have encouraged gene...
Background: To reduce expenditure on, and wastage of, drugs, some commissioners have encouraged gene...
Background: To reduce expenditure on, and wastage of, drugs, some commissioners have encouraged gene...
Background: The National Health Service (NHS) in England spends over £9 billion on prescription medi...
Objective: To investigate the relative impact of generic entry and NICE clinical guidelines on presc...
King S, Miani C, Exley J, Larkin J, Kirtley A, Payne RA. Impact of issuing longer- versus shorter-du...
Objective: To investigate the relative impact of generic entry and National Institute for Health and...
Background: To reduce expenditure on, and wastage of, drugs, some commissioners have encouraged gene...
Aims UK guidelines for type II diabetes leave the choice of glucose lowering therapies after metform...
This is the author accepted manuscript. The final version is available from the publisher via the DO...
Background: Two alternative basal analogue insulin treatments are available: insulin glargine (glarg...
OBJECTIVES: To investigate patterns of early repeat prescriptions and treatment switching over an 11...
Objectives: To investigate patterns of early repeat prescriptions and treatment switching over an 11...
Background: The National Health Service (NHS) in England spends over £9 billion on prescription medi...
BACKGROUND: To reduce expenditure on, and wastage of, drugs, some commissioners have encouraged gene...
Background: To reduce expenditure on, and wastage of, drugs, some commissioners have encouraged gene...
Background: To reduce expenditure on, and wastage of, drugs, some commissioners have encouraged gene...
Background: To reduce expenditure on, and wastage of, drugs, some commissioners have encouraged gene...
Background: The National Health Service (NHS) in England spends over £9 billion on prescription medi...
Objective: To investigate the relative impact of generic entry and NICE clinical guidelines on presc...
King S, Miani C, Exley J, Larkin J, Kirtley A, Payne RA. Impact of issuing longer- versus shorter-du...
Objective: To investigate the relative impact of generic entry and National Institute for Health and...
Background: To reduce expenditure on, and wastage of, drugs, some commissioners have encouraged gene...
Aims UK guidelines for type II diabetes leave the choice of glucose lowering therapies after metform...
This is the author accepted manuscript. The final version is available from the publisher via the DO...
Background: Two alternative basal analogue insulin treatments are available: insulin glargine (glarg...